Epilepsy with myoclonic absences - favourable response to add-on rufinamide treatment in 3 cases.

@article{Husler2011EpilepsyWM,
  title={Epilepsy with myoclonic absences - favourable response to add-on rufinamide treatment in 3 cases.},
  author={Martin H{\"a}usler and Gerhard Josef Kluger and Marina Nikanorova},
  journal={Neuropediatrics},
  year={2011},
  volume={42 1},
  pages={28-9}
}
BACKGROUND Epilepsy with myoclonic absences (EMA) is a rare epileptic syndrome with frequently poor response to antiepileptic treatment. Rufinamide (RUF) is a relatively new EMEA- and FDA-approved anticonvulsant licensed as an orphan drug for the adjunctive treatment of patients with Lennox-Gastaut syndrome. METHODS A retrospective data analysis in 3 patients was performed. RESULTS Add-on RUF treatment was initiated in 3 boys with EMA refractory to conventional antiepileptic therapy… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…